Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Statement Of Cash flows (Detail) - USD ($)
$ in Thousands

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Statement Of Cash flows (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2024	Sep. 01, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net Income (Loss)	$ (654)		$ 16,923	$ 8,355	$ 52,046
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization				51,306	51,295
Amortization of debt discount and issuance costs				11,628	1,373
Stock-based compensation	23,055	$ 22,400	6,373	41,711	19,110
Deferred income taxes, net				(4,163)	(9,268)
Contingent consideration	0		(34,292)	0	(31,266)
Non-cash interest income				0	(2,023)
Operating lease right of use asset amortization				12,749	10,203
Other				107	1,275
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable				(4,631)	8,315
Inventories				20,131	25,979
Prepaid expenses and other assets				(2,609)	(12,749)
Other assets					(707)
Accounts payable				1,780	(8,619)
Accrued expenses				5,360	(12,514)
Operating lease liabilities				(5,849)	(7,676)
Long-term liabilities				(141)	79
Total cash provided by operating activities				136,218	84,853
Cash flows from investing activities:
Acquisitions, net of cash acquired				0	(27,843)
Proceeds from maturity of marketable securities held to maturity				0	102,323
Additions to capitalized software costs				(2,774)	(2,736)
Purchases of property, plant and equipment				(20,137)	(25,135)
Purchase of intellectual property					0
Other investing activities					21
Total cash (used in) provided by investing activities				(21,621)	46,630
Cash flows from financing activities:
Proceeds from exercise of stock options				2,366	356
Payment of tax withholding obligation on vesting of restricted stock				(9,403)	(12,178)
Repayment of Convertible Senior Notes				(69,939)	(33)
Payment of earnout consideration				(7,375)	(7,298)
Proceeds from issuance of common stock, net					(13)
Total cash used in financing activities				(84,351)	(19,166)
Effect of exchange rate changes on cash and cash equivalents				2,395	(4,996)
Net increase (decrease) in cash and cash equivalents				32,641	107,321
Cash, cash equivalents and restricted cash, beginning of period				751,323	523,458
Cash and cash equivalents, end of period	$ 783,964		630,779	783,964	630,779
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases				24,087	1,129
Fair value of shares of common stock issued for contingent consideration earnouts				5,742	7,229
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition				$ 0	5,465
Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of shares of common stock issued for contingent consideration earnouts					7,229
Previously Reported
Cash flows from operating activities:
Net Income (Loss)			18,172		67,065
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					50,942
Amortization of debt discount and issuance costs					1,373
Stock-based compensation					19,110
Deferred income taxes, net					(9,756)
Contingent consideration			(34,292)		(31,266)
Non-cash interest income					(2,023)
Operating lease right of use asset amortization					10,203
Other					861
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable					8,315
Inventories					25,979
Prepaid expenses and other assets					(10,733)
Other assets					(707)
Accounts payable					(8,619)
Accrued expenses					(28,294)
Operating lease liabilities					(7,676)
Long-term liabilities					79
Total cash provided by operating activities					84,853
Cash flows from investing activities:
Acquisitions, net of cash acquired					(27,843)
Proceeds from maturity of marketable securities held to maturity					102,323
Additions to capitalized software costs					(2,736)
Purchases of property, plant and equipment					(25,135)
Purchase of intellectual property					0
Other investing activities					21
Total cash (used in) provided by investing activities					46,630
Cash flows from financing activities:
Proceeds from exercise of stock options					356
Payment of tax withholding obligation on vesting of restricted stock					(12,178)
Repayment of Convertible Senior Notes					(33)
Payment of earnout consideration					(7,298)
Proceeds from issuance of common stock, net					(13)
Total cash used in financing activities					(19,166)
Effect of exchange rate changes on cash and cash equivalents					(4,996)
Net increase (decrease) in cash and cash equivalents					107,321
Cash, cash equivalents and restricted cash, beginning of period					523,458
Cash and cash equivalents, end of period			630,779		630,779
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases					1,129
Previously Reported \| FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition					5,465
Previously Reported \| Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of shares of common stock issued for contingent consideration earnouts					7,229
Revenue Adjustments
Cash flows from operating activities:
Net Income (Loss)			(1,053)		(14,431)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					0
Amortization of debt discount and issuance costs					0
Stock-based compensation					0
Deferred income taxes, net					667
Contingent consideration			0		0
Non-cash interest income					0
Operating lease right of use asset amortization					0
Other					0
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable					0
Inventories					0
Prepaid expenses and other assets					(2,016)
Other assets					0
Accounts payable					0
Accrued expenses					15,780
Operating lease liabilities					0
Long-term liabilities					0
Total cash provided by operating activities					0
Cash flows from investing activities:
Acquisitions, net of cash acquired					0
Proceeds from maturity of marketable securities held to maturity					0
Additions to capitalized software costs					0
Purchases of property, plant and equipment					0
Purchase of intellectual property					0
Other investing activities					0
Total cash (used in) provided by investing activities					0
Cash flows from financing activities:
Proceeds from exercise of stock options					0
Payment of tax withholding obligation on vesting of restricted stock					0
Repayment of Convertible Senior Notes					0
Payment of earnout consideration					0
Proceeds from issuance of common stock, net					0
Total cash used in financing activities					0
Effect of exchange rate changes on cash and cash equivalents					0
Net increase (decrease) in cash and cash equivalents					0
Cash, cash equivalents and restricted cash, beginning of period					0
Cash and cash equivalents, end of period			0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases					0
Revenue Adjustments \| FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition					0
Revenue Adjustments \| Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of shares of common stock issued for contingent consideration earnouts					0
Other Adjustments
Cash flows from operating activities:
Net Income (Loss)			(196)		(588)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					353
Amortization of debt discount and issuance costs					0
Stock-based compensation					0
Deferred income taxes, net					(179)
Contingent consideration			0		0
Non-cash interest income					0
Operating lease right of use asset amortization					0
Other					414
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable					0
Inventories					0
Prepaid expenses and other assets					0
Other assets					0
Accounts payable					0
Accrued expenses					0
Operating lease liabilities					0
Long-term liabilities					0
Total cash provided by operating activities					0
Cash flows from investing activities:
Acquisitions, net of cash acquired					0
Proceeds from maturity of marketable securities held to maturity					0
Additions to capitalized software costs					0
Purchases of property, plant and equipment					0
Purchase of intellectual property					0
Other investing activities					0
Total cash (used in) provided by investing activities					0
Cash flows from financing activities:
Proceeds from exercise of stock options					0
Payment of tax withholding obligation on vesting of restricted stock					0
Repayment of Convertible Senior Notes					0
Payment of earnout consideration					0
Proceeds from issuance of common stock, net					0
Total cash used in financing activities					0
Effect of exchange rate changes on cash and cash equivalents					0
Net increase (decrease) in cash and cash equivalents					0
Cash, cash equivalents and restricted cash, beginning of period					0
Cash and cash equivalents, end of period			$ 0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases					0
Other Adjustments \| FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition					0
Other Adjustments \| Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of shares of common stock issued for contingent consideration earnouts					$ 0